Introduction
============

Diamond-Blackfan anemia (DBA) (OMIM\# 105650) is an inherited bone marrow failure disorder that typically manifests in children under the age of one year. While the central phenotype is pure red cell aplasia, developmental delay and a number of physical malformations are also linked to DBA.^[@b1-1030949]^ These include (but are not limited to) craniofacial malformations, growth retardation, abnormalities in the extremities, heart defects, as well as urogenital defects.^[@b2-1030949],[@b3-1030949]^ While most patients (\>90%) are diagnosed within the first year of life, a minority present with anemia at birth. Hydrops fetalis due to severe intrauterine anemia is considered a very rare manifestation of DBA.^[@b4-1030949]^ To date, a total of 10 cases of DBA-associated hydrops have been reported in single cases.^[@b5-1030949]--[@b13-1030949]^ The clinical outcome of these patients was poor as compared to typical DBA (3 patients died perinatally, 4 patients were steroid unresponsive, 2 patients required steroid therapy, and 1 had unknown outcome).

Almost all of the mutations linked to DBA have been found in genes coding for ribosomal proteins (RPs).^[@b14-1030949]^ These RPs include: eS7 (RPS7), uS8 (RPS15A), eS10 (RPS10), eS17 (RPS17), eS19 (RPS19), eS24 (RPS24), eS26 (RPS26), eS27 (RPS27), eS28 (RPS28), uS14 (RPS29), uL18 (RPL5), uL5 (RPL11), eL15 (RPL15), eL18 (RPL18), uL24 (RPL26), eL27 (RPL27), eL31 (RPL31), uL29 (RPL35) and eL33 (RPL35A).^[@b15-1030949]--[@b28-1030949]^ The *RPL15* gene has so far been reported in one patient who carried a large monoallelic microdeletion involving this gene.^[@b23-1030949]^ Non-RP genes linked to DBA, albeit very rarely involved, are *TSR2* and *GATA1*.^[@b26-1030949],[@b29-1030949]^ RP gene aberrations lead to haploinsufficiency, and in many cases result in reduction in the respective RP which impairs ribosome biogenesis, affecting both the processing pathways of pre-rRNA maturation and the assembly of the large or small ribosomal subunit.^[@b30-1030949],[@b31-1030949]^ TP53 is a tumor suppressor protein and transcription factor that stabilizes in response to cell stress, such as DNA damage or nucleolar stress induced by ribosome biogenesis defects.^[@b32-1030949],[@b33-1030949]^ Depending on the level of stress, stabilized TP53 will induce cell arrest, DNA repair, senescence and/or apoptosis. This pathway has been prominently implicated in the pathogenesis of DBA, with a number of studies suggesting that TP53 stabilization lies at the heart of the loss of erythroid progenitor cells in DBA bone marrow.^[@b34-1030949]--[@b36-1030949]^ In addition to activating apoptosis, DBA-linked RP gene mutations can impair cellular differentiation, alter the landscape of mRNAs on ribosomes, and induce autophagy.^[@b36-1030949]--[@b38-1030949]^

Therapy in DBA depends on the severity of anemia and on the response to oral glucocorticosteroids (GCS). GCS-non-responders receive chronic blood transfusions or can undergo hematopoietic stem cell transplantation (HSCT) which is often delayed because patients can achieve treatment independence.^[@b39-1030949]^ For unknown reasons, 20% of all DBA cases can become independent of steroid treatment and/or blood transfusions by the age of 25 years.^[@b39-1030949],[@b40-1030949]^ To date, however, there are no predictive genetic markers that could improve decision making for timely HSCT. Given the significant risks that are associated with HSCT,^[@b41-1030949]^ especially if a matched sibling donor is not available, such predictive markers would be very valuable.

Here we describe 6 DBA cases associated with mutations in ribosomal protein gene *RPL15*. These patients display an unexpectedly high rate of hydrops fetalis and treatment independence, pointing to a new genotype-phenotype correlation in DBA which could be important for risk stratification.

Methods
=======

Patients
--------

Diagnosis of DBA was made based on typical features including aregenerative anemia with erythroid hypoplasia.^[@b1-1030949]^ Written informed consent was obtained from patients and/or parents prior to inclusion in this study, which was performed in accordance with the ethical standards of the Declaration of Helsinki. The study was approved by the institutional ethics committee (University of Freiburg, IRB n. 205/99 and n. 351/17).

Cell culture
------------

Lymphoblastoid cell lines (LCLs) were derived from Epstein-Barr virus (EBV)-immortalization of peripheral mononuclear cells isolated from whole blood using Ficoll (GE Life Sciences) and grown in RPMI (Gibco) containing 10% fetal calf serum (FCS), 1% L-glutamine, and 1% penicillin/streptomycin, as previously described.^[@b42-1030949]^

DNA sequencing and bioinformatics
---------------------------------

Targeted Sanger sequencing was performed as previously reported.^[@b43-1030949]^ Primer sequences are available upon request. Pathogenicity of mutations, evolutionary conservation across species, and the physicochemical difference between amino acids were evaluated using standard prediction tools as outlined in *Online Supplementary Table S1*.

Details of pre-rRNA processing analysis, Northern blots, polysome profiling, measurement of growth rate and *de novo* protein synthesis are available in the *Online Supplementary Methods*.

Erythroid red cell culture assays
---------------------------------

Erythroid red cell culture assays were performed as previously described.^[@b36-1030949],[@b44-1030949]^ Antibodies and stains for FACS analysis were PC7 or PE conjugated CD34 (Beckman coulter, Brea, CA, USA), APC conjugated CD36 (BD Biosciences San Jose, CA, USA), PE conjugated α4 integrin (Miltenyi, Paris, France), APC conjugated Band 3 (kindly provided by Mohandas Narla's lab, NYBC, New York, USA), PE/Cy7 conjugated IL-3R (Miltennyi, Paris, France), PE/Cy7 (PE)-coupled GPA (Life Technologies Carlsbad, CA, USA), and DAPI (Sigma). FACS analysis was conducted on a BD Biosciences Influx flow cytometer (BD Biosciences San Jose, CA, USA). Data were analyzed using Kaluza software (Beckman Coulter, Brea, CA, USA). Antibodies for western blotting were TP53 (Sigma \#5816), phospho-TP53 (Ser15, Cell Signaling), p21 (Cell Signaling \#2947), actin (Sigma \#Ac-15), and eL15 (Abcam \#ab130992). Primers for real-time PCR used are as follows: TaqMhupRPL15F: CAGCCATCAGGTAAGCCAAGA; TaqMhuRPL15R: CAGCGGACCCTCAGAAGAAA; TaqMhupp21F: TTGCTGCCGCATGGG, TaqMhup21R: CCTTGTGGAGCCGGAGCT; TaqMhupactinF: CTGGAACGGTGAAGGTGACA; TaqMhupactinR: AAGGGACTTCCTGTAACAACGCA; TGTAGTGGATGGTGGTACAGTCAGA; TaqMB2MhF: GCGGCATCTTCAAACCTCC; *TaqMB2MhR*: TGACTTTGTCACAGCCCAAGATA. Real-time PCR was performed using the ABI 7900 Real Time PCR system and Taqman PCR mastermix (Life Technologies Carlsbad, CA, USA). Quantification of gene amplification was performed in duplicate using ΔΔCt method. The expression level of each gene was normalized using the housekeeping genes: actin, and β2 microglobulin.

Results
=======

Identification of novel *RPL15* mutations in 6 patients within EuroDBA registries
---------------------------------------------------------------------------------

Approximately 30% of all registered DBA patients who have been tested for mutations in the most common DBA-linked genes (*RPS19, RPL5, RPL11, RPS10, RPS26, RPS7, RPS17, RPS24*, and *RPL35a*) still do not have an established genotype. Because a whole gene deletion of *RPL15* has been reported before in one DBA patient but not in our cohorts,^[@b23-1030949]^ we used targeted Sanger sequencing of *RPL15* to determine if mutations in this gene could be driving disease in patients without an established genotype. The national patient registries from EuroDBA partners in Germany, France, Italy and Israel were included in this study. As of November 2017, these cohorts represent a total of 985 patients. A complete description of the history and composition of the EuroDBA consortium has been recently published.^[@b45-1030949]^ Study outline and screening strategy are illustrated in *Online Supplementary Figure S1*.

Four unrelated DBA patients from the German, and one each from the French and Israeli registries were identified carrying mutations in the *RPL15* gene (NM_001253379.1), which encodes ribosomal protein eL15/RPL15 ([Figure 1A and B](#f1-1030949){ref-type="fig"}). Out of the 6 *RPL15*-mutated patients, 3 unrelated patients (P1-3) carried the same novel indel mutation c.242dupA altering the tyrosine at position 81 to a stop codon: p.Tyr81\* ([Table 1](#t1-1030949){ref-type="table"} and *Online Supplementary Table S1*). Patient 4 (P4) carried another stop-gain mutation in *RPL15* resulting in an even earlier protein truncation: c.85C\>T; p.Gln29\*. The Exome Aggregation Consortium (ExAC) reports that *RPL15* is very intolerant to loss-of-function mutations with no reported cases present in over 60,000 individuals (pLI score =0.96), strongly suggesting the novel mutations p.Gln29\* and p.Tyr81\* found in our patients are highly deleterious (*Online Supplementary Table S1*). In addition, the analysis of family trios revealed that hotspot mutations arose *de novo* in two families ([Table 1](#t1-1030949){ref-type="table"} and [Figure 1A](#f1-1030949){ref-type="fig"}), while one patient (P1/DE071) inherited the mutation from her father who had been categorized as a DBA silent carrier due to very high erythrocyte adenosine deaminase (eADA) levels. The remaining two point mutations c.29T\>C; p.Leu10Pro (P5) and c.458A\>C; p.Lys153Thr (P6) affect highly conserved residues and, based on results from *in silico* prediction, are probably deleterious (*Online Supplementary Table S1*). Biomuta, DMDM, the Exac/GnomAD databases, and NCBI do not report any variants in the codon for Leu10. The GnomAD population database reports one variant in Lys153 (Lys153Arg; rs370700905) identified in 33 out of 232840 total alleles.

![Mutations in *RPL15* are identified in patients with Diamond-Blackfan anemia (DBA). (A) Six unrelated pedigrees of individuals affected by DBA associated with *RPL15* mutations. All families have one DBA-affected individual who is also a mutation carrier, as indicated with filled squares (male) or circles (female). Unaffected individuals are indicated by unfilled symbols. Unaffected mutation carriers are denoted by a dot symbol (●). NA: unaffected family members who were not investigated for the presence of mutations. Families 1--4 harbor heterozygous stopgain mutations in *RPL15*; families 5--6 carry heterozygous missense *RPL15* mutations. (B) Schematic representation of human *RPL15* depicting localization of the mutations identified in families 1--6.](103949.fig1){#f1-1030949}

###### 

Clinical characteristics of patients with *RPL15* mutations.

![](103949.tab1)

Genotype-phenotype association for truncating *RPL15* mutations: severe hematologic phenotype and rapid acquisition of treatment independence
---------------------------------------------------------------------------------------------------------------------------------------------

All of the individuals with mutations in *RPL15* presented with typical bone marrow erythroid hypoplasia, elevated eADA, and most of them presented with increased fetal hemoglobin (HbF) levels ([Table 1](#t1-1030949){ref-type="table"}). Notably, hydrops fetalis (considered the most severe hematologic phenotype of DBA) was associated only with truncating *RPL15* mutations. The affected fetuses P2-4 required between four and nine intrauterine transfusions ([Table 1](#t1-1030949){ref-type="table"}). One individual (P2) with the p.Tyr81\* hotspot mutation presented with various physical malformations, while the dysmorphic features in other patients were less severe ([Table 1](#t1-1030949){ref-type="table"}). Unexpectedly, all 3 patients carrying p.Tyr81\* substitution (P1-3) attained a rapid treatment independence both with and without steroid treatment ([Figure 2A](#f2-1030949){ref-type="fig"}), while the fourth patient with the *RPL15* mutation c.85C\>T; p.Gln29\* responded to steroids; however, the therapy was discontinued due to overt toxicity.

![Longitudinal mutations in *RPL15* are identified in individuals diagnosed with Diamond-Blackfan anemia (DBA). (A) Clinical evolution of P1-P3 carrying truncating hotspot mutation *RPL15* p.Tyr81\*. Patient 1 manifested with DBA after birth and after one transfusion achieved spontaneous remission at the age of six months. A relapse occurred five years later and after a short course of steroids the patient attained treatment independence. Patients 2 and 3 had a similar clinical course with hydrops fetalis and prenatal intrauterine transfusions, and achieved treatment independence either spontaneously or after one course of steroids. (B) Sanger sequencing results of the recurring mutation in *RPL15* from initial diagnoses as well as post remission. Arrows indicate the inserted A nucleotide. FUP: follow up; BM: bone marrow; PB: peripheral blood; LCL: lymphoblastoid cell lines.](103949.fig2){#f2-1030949}

Based on published observations of genetic revertant mosaicism as a "repair mechanism" in other bone marrow failure syndromes,^[@b46-1030949]^ we speculated that the hematologic remission in our patients was attained *via* genetic reversion (e.g. uniparental disomy). Sequencing of DNA in P1-3 either at multiple time points or after the acquisition of treatment independence did not reveal any changes in mutation load ([Figure 2B](#f2-1030949){ref-type="fig"}).

Mutations in *RPL15* recapitulate specific pre-rRNA processing defects found in RP depleted cells
-------------------------------------------------------------------------------------------------

Mutations in DBA-linked RP genes result in haploinsufficiency of the encoded RP. Since the majority of RPs incorporate into pre-ribosomal particles in a progressive manner concurrently with pre-rRNA maturation, a lack of one RP impairs pre-rRNA processing in an explicit way that is reproducible in most cell types.^[@b47-1030949]^ *Online Supplementary Figure S2* illustrates the normal pre-rRNA processing pathway that begins with a single transcribed strand of 47S pre-rRNA that then undergoes a complex series of cleavages and trimmings to ultimately result in the mature 18S, 28S, and 5.8S strands of rRNA found in ribosomes. To investigate the functional consequences of the newly identified RP gene mutations reported here, EBV-immortalized lymphoblast cell lines (LCLs) were generated and the pre-rRNA processing of these LCLs was compared to HeLa cells depleted of eL15.

As previously reported,^[@b23-1030949]^ depletion of eL15 in HeLa cells resulted in a decrease in 32S and 12S pre-rRNAs ([Figure 3A and C](#f3-1030949){ref-type="fig"}). This was accompanied by the accumulation of the 36S and 36S-C precursors, which are inconspicuous in normal cells, and a concomitant drop in 32.5S pre-rRNA ([Figure 3B](#f3-1030949){ref-type="fig"}). In addition, these cells displayed lower levels of 30S pre-rRNA and higher levels of 41S and 18S-E pre-rRNAs ([Figure 3A and C](#f3-1030949){ref-type="fig"}). This phenotype indicates that depletion of eL15 affects cleavage of the ITS1 at site 2, which promotes direct cleavage of early precursors at site E and formation of 18S-E and 36S pre-rRNAs. The 36S precursor is then trimmed by the 5'-3' exoRNase XRN2 to produce the 36S-C and 32.5S pre-rRNAs.^[@b48-1030949]^ Sucrose gradient analyses confirmed the efficiency of the eL15 siRNAs in reducing the free 60S subunit peak and inducing the formation of half-mers, as expected from the deficiency of an RPL protein (*Online Supplementary Figure S3*). Consistent with eL15 partial loss-of-function, an increase of 36S and 36S-C precursors was observed in the patient LCLs carrying the eL15 p.Tyr81\* variant ([Figure 3B](#f3-1030949){ref-type="fig"}). In addition, both cell lines displayed a marked increase of the amount of 18S-E precursors translating into a higher 18S-E/21S ratio, similar to eL15-depleted cells ([Figure 3A and C](#f3-1030949){ref-type="fig"}). This phenotype is similar to that previously observed in LCLs harboring a large heterozygous deletion in *RPL15*.^[@b23-1030949]^

![Mutations in *RPL15* recapitulate specific pre-rRNA processing defects found in eL15 depleted cells. (A) Northern blot analysis of siRNA-treated HeLa cells or lymphoblastoid cell lines (LCLs) derived from individuals with Diamond-Blackfan anemia (DBA). Radiolabeled probes against ITS2 (top panel), ITS1 (middle panel), 18S or 28S (lower panel) rRNA sequences were used to blot 3μg total RNA isolated from cells. (B) Longer exposures of upper molecular weight pre-rRNA species observed in the northern blots from (A). Intensity profiles of the lanes is shown in the right-hand boxes. (C) Quantification of rRNA precursors in siRNA-treated HeLa cells (top) or LCLs (bottom) derived from individuals with DBA. The results of single experiments performed for each sample are displayed as multiple bars. Pre-rRNA ratios are normalized by dividing by the mean of the control samples.](103949.fig3){#f3-1030949}

*RPL15* mutations impair 60S ribosomal subunit formation, cell proliferation, and *de novo* protein synthesis
-------------------------------------------------------------------------------------------------------------

Defective processing of pre-rRNA in cells often results in cells that are unable to fully form ribosomal subunits. As such, pathogenic variants of RPs linked to DBA very often impair biogenesis of ribosomal subunits in LCLs.^[@b37-1030949]^ Polysome profiling was performed to determine if the observed pre-rRNA biogenesis defects resulted in impaired biogenesis of large ribosomal subunits. [Figure 4A](#f4-1030949){ref-type="fig"} shows polysome profiles of LCL extracts derived from a healthy individual or patients carrying the p.Tyr81\* variant in eL15. As expected, the LCLs from the healthy individual reveal an equivalent ratio of 40S to 60S peaks, while the LCLs derived from patients reveal a substantial reduction of 60S peaks compared to 40S peaks. These results suggest the pre-rRNA defects depicted in [Figure 3](#f3-1030949){ref-type="fig"} go on to impair biogenesis of large 60S ribosomal subunits.

![*RPL15* mutations impair cell proliferation, *de novo* protein synthesis, and 60S ribosomal subunit formation. (A) Representative (n=3) polysome profiles of lymphoblastoid cell line (LCL) extracts derived from healthy individuals or individuals with Diamond-Blackfan anemia (DBA) carrying the *RPL15* c.242dupA mutation. The 40S small subunit, 60S subunit, 80S monosome, and polysomes are labeled. Arrows point to the reduced 60S peaks in cells with *RPL15* mutations. (B) Growth curve of LCLs derived from individuals with DBA or healthy controls over six days. Standard Deviations for healthy control-1 cells on days 1-5 are 2.6e4, 1.5e4, 3.8e4, 6.9e4, 1.0e5; healthy control-2 cells are 8.8e3, 3.0e4, 2.9e4, 7.5e4, 8.5e4; *RPL15* c.242dupA-1 are 2.1e4, 1.9e4, 1.6e4, 2.3e4, 2.2e4; and *RPL15* c.242dupA-2 are 9.5e3, 1.7e4, 1.7e4, 2.2e4, 2.5e4. (C) Measurement of the amount of *de novo* protein synthesis in 30 minutes in LCLs derived from healthy individuals or a DBA patient carrying the eL15 Tyr81\* variant using Click-iT® analysis.](103949.fig4){#f4-1030949}

The impairment of ribosome biogenesis in cells can slow the rate of protein synthesis and cell proliferation. RP gene mutations linked to DBA are reported to slow the rate of cell proliferation and increase apoptosis.^[@b36-1030949]^ In agreement, we found that LCLs carrying the eL15 p.Tyr81\* variant proliferated far more slowly than healthy control LCLs ([Figure 4B](#f4-1030949){ref-type="fig"}). Moreover, measurement of *de novo* protein synthesis by Click-iT® labeling analysis revealed a severe reduction in the synthesis rate of LCLs carrying the eL15 variant ([Figure 4C](#f4-1030949){ref-type="fig"} and *Online Supplementary Figure S4*).

Erythroid cell culture assays of primary *RPL15* c.242dupA cells reveal severe proliferation defects, differentiation delays, and TP53-related apoptosis
--------------------------------------------------------------------------------------------------------------------------------------------------------

Erythroid cell culture assays show that hematopoietic progenitor cells can reveal reduced proliferation rates, delayed differentiation, and increased TP53-induced apoptosis in a manner that is largely dependent on which RP gene is haploinsufficient.^[@b36-1030949]^ We performed these assays in CD34^+^ cells isolated from bone marrow mononuclear cells (BM-MNC) of 2 patients with truncating *RPL15* mutations p.Tyr81\*. Compared to healthy control, patients BM-MNC showed a higher rate of cell death and apoptosis ([Figures 5B](#f5-1030949){ref-type="fig"} and *Online Supplementary Figure S5*). FACS analysis revealed CD36 downregulation and CD34 upregulation on both day 7 and day 9 in the Tyr81\* mutant cells as compared to healthy controls ([Figures 5C](#f5-1030949){ref-type="fig"} and *Online Supplementary Figure S5*). In addition, Tyr81\* mutant cells retain a higher expression of the IL3 receptor that is normally down-regulated in the erythroid lineage, and express less erythroid-specific glycophorin A (GPA), Band-3, or alpha-4 integrin compared to healthy control cells ([Figure 5D and E](#f5-1030949){ref-type="fig"} and *Online Supplementary Figure S5*). Additionally, expression of *RPL15* mRNA was lower ([Figure 5F](#f5-1030949){ref-type="fig"}) and of p21 mRNA higher in Tyr81\* mutant cells ([Figure 5G](#f5-1030949){ref-type="fig"}). The observed p21 overexpression is likely TP53-mediated, as supported by western blot analysis confirming an increase in TP53 phosphorylation and increased p21 protein expression ([Figure 5H](#f5-1030949){ref-type="fig"}). Finally, TP53 protein stabilization was observed in Tyr81\* mutant patient cells ([Figure 5I](#f5-1030949){ref-type="fig"}).

![Erythroid cell culture assays of primary *RPL15* c.242dupA erythroid progenitor and precursor cells reveal severe erythroid proliferation defects, differentiation delays, and TP53-related apoptosis. (A) Proliferation curve of erythroid cells isolated from CD34^+^ cells from peripheral blood of 2 individuals with Diamond-Blackfan anemia (DBA) and an *RPL15* mutation or a healthy control over nine days in liquid culture medium. (B) FACS analysis results of the percent of dead cells or apoptotic cells staining positive for Annexin V on days 7, 10, and 13 after plating in red cell culture medium. (C) FACS analysis results on days 7 and 9 of the percent of cells staining positive for CD36 and CD34. (D) FACS analysis results on days 7 and 9 of cells staining positive for IL3R and GPA. (E) FACS analysis results on days 7 and 9 of cells staining positive for Alpha-4 and Band-3. (F) Real-time PCR results of the ratio between *RPL15* mRNA and actin mRNA in cells. (G) Real-time PCR results of the ratio between p21 mRNA and actin mRNA in cells. (H) Western blot analysis of cells from a healthy control or an individual with DBA and a mutation in *RPL15* using antibodies against phosphorylated TP53, p21, eL15, or actin on day 7. (I) Western blot analysis of cells from a healthy control or an *RPL15* with DBA and a mutation in *RPL15* using antibodies against TP53 or actin on days 7 and 9.](103949.fig5){#f5-1030949}

Discussion
==========

At present there are 19 RP genes associated with DBA, representing almost one-quarter of the 80 cytoplasmic RPs in human cells. Here, we describe a novel genetic subgroup of DBA due to mutations in the *RPL15* gene and identify the truncating mutation c.242dupA; p.Tyr81\* as a recurrent genetic cause in 3 unrelated patients. The experimental results show that LCLs carrying the p.Tyr81\* variant reveal an array of molecular defects typically associated with a ribosomopathy phenotype. These include impaired pre-rRNA processing, reduced 60S ribosomal subunit formation, a reduction in *de novo* protein synthesis, and impaired cell proliferation. Further, mutant LCLs phenocopied biological changes observed in HeLa cells depleted of eL15. These results, similar to previous reports that DBA-linked RP mutations impair pre-rRNA processing, indicate that the *RPL15* mutations reported here are likely pathogenic and result in haploinsufficiency.

The altered ribosome biogenesis may explain the observed reduction in global protein synthesis, substantiating previous reports discussing altered translation of specific mRNAs in DBA-mutant cells as a key component of disease pathogenesis.^[@b49-1030949],[@b50-1030949]^ In support of this pathogenesis, we also found that hematopoietic stem cells with the eL15 Tyr81\* variant that were induced to differentiate into erythrocytes revealed a substantial decrease in the number of erythroid colonies and delays in differentiation. These findings, in addition to increased apoptosis, TP53 stabilization, and p21 overexpression in *RPL15*-mutant hematopoiesis, suggest that eL15 plays a critical role in ribosome biogenesis and that the reduction of the protein by genetic haploinsufficiency drives severe stress in the nucleolus.

Hydrops fetalis arising from severe intrauterine anemia is an uncommon manifestation of DBA with 10 cases reported so far. The clinical outcome of these patients was poor and, unexpectedly, no spontaneous remission was observed. In contrast, 50% (3 of 6) of all patients with *RPL15* mutations reported in our study showed prenatal manifestation with the necessity of intrauterine transfusions. Remarkably, the hydrops cases were observed only in the subgroup of patients carrying protein truncating mutations p.Tyr81\* and p.Gln29\*, with prevalence of hydrops reaching 75% (3 of 4).

A substantial percentage of individuals with DBA spontaneously achieve treatment independence at some point; however, the reasons for this remain elusive and no predictive biomarkers exist.^[@b39-1030949]^ In line with this, another unexpected finding was the rapid and sustained treatment independence achieved within four to 16 months after birth in all 3 unrelated DBA patients with the recurrent p.Tyr81\* mutation. Although Patient 1 relapsed five years after achieving spontaneous remission, a short steroid course was very effective and resulted in treatment independence. These observations suggest that p.Tyr81\* mutation carriers can achieve treatment independence with or without a previous course of steroids, and that a genotype itself may be an important biomarker for the expected clinical course. Our findings might help prospective clinical stratification to determine which individuals are more likely to become treatment independent without the need for HSCT. The reasons why the specific mutation p.Tyr81\* drives treatment independence remain unknown and cannot be explained by a potential genetic reversion, which was not observed in our patients. One tempting speculation is that the remaining wild-type allele compensates for the haploinsufficiency (e.g. by epigenetic mechanisms) in the adult hematopoiesis, but the compensation might not be present or sufficient in the fetus. These findings warrant further studies on the future availability of more patient material.

In conclusion, our study establishes germline point mutations in the *RPL15* gene as novel genetic etiology of DBA. Half of the individuals carrying these mutations manifest with hydrops fetalis, a phenotype that is very rarely observed in DBA patients. Finally, we establish that a recurrent DBA genotype, eL15 p.Tyr81\*, is linked to treatment independence.
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